Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28


Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome.

Cohen AJ, Saiakhova A, Corradin O, Luppino JM, Lovrenert K, Bartels CF, Morrow JJ, Mack SC, Dhillon G, Beard L, Myeroff L, Kalady MF, Willis J, Bradner JE, Keri RA, Berger NA, Pruett-Miller SM, Markowitz SD, Scacheri PC.

Nat Commun. 2017 Feb 7;8:14400. doi: 10.1038/ncomms14400.


Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factor-beta signaling in mouse intestinal neoplasms.

Morris SM, Davison J, Carter KT, O'Leary RM, Trobridge P, Knoblaugh SE, Myeroff LL, Markowitz SD, Brett BT, Scheetz TE, Dupuy AJ, Starr TK, Grady WM.

Int J Cancer. 2017 Feb 15;140(4):853-863. doi: 10.1002/ijc.30491. Epub 2016 Nov 7.


Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival.

Fink SP, Myeroff LL, Kariv R, Platzer P, Xin B, Mikkola D, Lawrence E, Morris N, Nosrati A, Willson JK, Willis J, Veigl M, Barnholtz-Sloan JS, Wang Z, Markowitz SD.

Oncotarget. 2015 Oct 13;6(31):30500-15. doi: 10.18632/oncotarget.5921.


Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits.

Corradin O, Saiakhova A, Akhtar-Zaidi B, Myeroff L, Willis J, Cowper-Sal lari R, Lupien M, Markowitz S, Scacheri PC.

Genome Res. 2014 Jan;24(1):1-13. doi: 10.1101/gr.164079.113. Epub 2013 Nov 6.


Two Distinct Categories of Focal Deletions in Cancer Genomes.

Rajaram M, Zhang J, Wang T, Li J, Kuscu C, Qi H, Kato M, Grubor V, Weil RJ, Helland A, Borrenson-Dale AL, Cho KR, Levine DA, Houghton AN, Wolchok JD, Myeroff L, Markowitz SD, Lowe SW, Zhang M, Krasnitz A, Lucito R, Mu D, Powers RS.

PLoS One. 2013 Jun 21;8(6):e66264. doi: 10.1371/journal.pone.0066264. Print 2013.


H3K4me3 inversely correlates with DNA methylation at a large class of non-CpG-island-containing start sites.

Balasubramanian D, Akhtar-Zaidi B, Song L, Bartels CF, Veigl M, Beard L, Myeroff L, Guda K, Lutterbaugh J, Willis J, Crawford GE, Markowitz SD, Scacheri PC.

Genome Med. 2012 May 28;4(5):47. doi: 10.1186/gm346.


Epigenomic enhancer profiling defines a signature of colon cancer.

Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, Balasubramanian D, Myeroff L, Lutterbaugh J, Jarrar A, Kalady MF, Willis J, Moore JH, Tesar PJ, Laframboise T, Markowitz S, Lupien M, Scacheri PC.

Science. 2012 May 11;336(6082):736-9. doi: 10.1126/science.1217277. Epub 2012 Apr 12.


BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.

Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR.

Cancer Res. 2009 Oct 1;69(19):7577-86. doi: 10.1158/0008-5472.CAN-09-0773. Epub 2009 Sep 8.


Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer.

Nibbe RK, Markowitz S, Myeroff L, Ewing R, Chance MR.

Mol Cell Proteomics. 2009 Apr;8(4):827-45. doi: 10.1074/mcp.M800428-MCP200. Epub 2008 Dec 19.


Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.

Biswas S, Trobridge P, Romero-Gallo J, Billheimer D, Myeroff LL, Willson JK, Markowitz SD, Grady WM.

Genes Chromosomes Cancer. 2008 Feb;47(2):95-106.


Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.

Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD.

J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32.


SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers.

Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8412-7. Epub 2003 Jun 26.


HLTF gene silencing in human colon cancer.

Moinova HR, Chen WD, Shen L, Smiraglia D, Olechnowicz J, Ravi L, Kasturi L, Myeroff L, Plass C, Parsons R, Minna J, Willson JK, Green SB, Issa JP, Markowitz SD.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4562-7. Epub 2002 Mar 19. Erratum in: Proc Natl Acad Sci U S A 2002 Jun 25;99(13):9081.


Chromosomal autonomy of hMLH1 methylation in colon cancer.

Li H, Myeroff L, Kasturi L, Krumroy L, Schwartz S, Willson JK, Stanbridge E, Casey G, Markowitz S.

Oncogene. 2002 Feb 21;21(9):1443-9.


Mutation Detection inTGF-β Receptors.

Grady WM, Myeroff LL, He H, Markowitz S.

Methods Mol Med. 2001;50:99-111. doi: 10.1385/1-59259-084-5:99.


Mutation detection in the TGF-beta receptors and smad genes: RT-PCR and sequencing.

Myeroff LL, He H, Fink SP, Markowitz S.

Methods Mol Biol. 2000;142:139-47. Review. No abstract available.


Detection of TGF-beta type II receptor hot-spot mutations: the BAT-RII assay.

Myeroff LL, Markowitz S.

Methods Mol Biol. 2000;142:133-7. Review. No abstract available.


Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.

Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK, Markowitz S.

Cancer Res. 1999 Jan 15;59(2):320-4.


Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.

Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, Markowitz S.

Cancer Res. 1998 Jul 15;58(14):3101-4.


What's new with RII?

Grady W, Rajput A, Myeroff L, Markowitz S.

Gastroenterology. 1997 Jan;112(1):297-302. No abstract available.


Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer.

Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B.

Cancer Res. 1995 Dec 1;55(23):5548-50.


A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability.

Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, et al.

Cancer Res. 1995 Dec 1;55(23):5545-7.


Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells.

Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JK, et al.

J Biol Chem. 1995 Sep 15;270(37):22044-9.


Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al.

Science. 1995 Jun 2;268(5215):1336-8.


Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival

Markowitz S, Hines JD, Lutterbaugh J, Myeroff L, Mackay W, Gordon N, Rustum Y, Luna E, Kleinerman J.

Clin Cancer Res. 1995 Apr;1(4):441-5.


Nm23--into the basement (membrane)

Myeroff LL, Markowitz SD.

J Natl Cancer Inst. 1994 Dec 21;86(24):1815-7. No abstract available.


Supplemental Content

Loading ...
Support Center